Suppr超能文献

强力霉素和米诺环素的安全性:一项系统评价

Safety of doxycycline and minocycline: a systematic review.

作者信息

Smith Kelly, Leyden James J

机构信息

Warner Chilcott Laboratories, Rockaway, NJ 07866, USA.

出版信息

Clin Ther. 2005 Sep;27(9):1329-42. doi: 10.1016/j.clinthera.2005.09.005.

Abstract

OBJECTIVE

The goal of this review was to summarize the available literature covering the safety profiles of oral doxycycline and minocycline.

METHODS

Scientific literature published between 1966 and August 2003 was searched using the MEDLINE, EMBASE, and Biosis databases (search terms: minocycline or doxycycline, each paired with adverse reaction, adverse event, and side effect, and doxycycline or minocycline with the limits English language, human, and clinical trials). Safety information was collected from case reports and clinical trials. Adverse event (AE) rates in the United States were calculated by comparing data from the MedWatch AE reporting program used by the US Food and Drug Administration (FDA) with the number of new prescriptions dispensed for each drug from January 1998 to August 2003.

RESULTS

Between 1966 and 2003, a total of 130 and 333 AEs were published in case reports of doxycycline and minocycline, respectively. In 24 doxycycline clinical trials (n = 3833) and 11 minocycline trials (n = 788), the ranges in incidence of AEs were 0% to 61% and 11.7% to 83.3%, respectively. Gastrointestinal AEs were most common with doxycycline; central nervous system and gastrointestinal AEs were most common with minocycline. From January 1998 to August 2003, the FDA MedWatch data contained 628 events for doxycycline and 1099 events for minocycline reported in the United States. Approximately 47,630,000 doxycycline and 15,234,000 minocycline new prescriptions were dispensed in the United States during that period, yielding event rates of 13 per million for doxycycline and 72 per million for minocycline, based on FDA data.

CONCLUSIONS

Between 1998 and 2003, doxycycline was prescribed 3 times as often as minocycline. The incidence of AEs with either drug is very low, but doxycycline had fewer reported AEs. Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.

摘要

目的

本综述的目的是总结涵盖口服多西环素和米诺环素安全性概况的现有文献。

方法

使用MEDLINE、EMBASE和Biosis数据库检索1966年至2003年8月发表的科学文献(检索词:米诺环素或多西环素,分别与不良反应、不良事件和副作用配对,以及多西环素或米诺环素,并限定语言为英语、研究对象为人类且为临床试验)。从病例报告和临床试验中收集安全性信息。通过将美国食品药品监督管理局(FDA)使用的MedWatch不良事件报告项目的数据与1998年1月至2003年8月每种药物的新处方配药数量进行比较,计算美国的不良事件(AE)发生率。

结果

1966年至2003年期间,多西环素和米诺环素的病例报告中分别共发表了130例和333例不良事件。在24项多西环素临床试验(n = 3833)和11项米诺环素试验(n = 788)中,不良事件的发生率范围分别为0%至6I%和11.7%至83.3%。胃肠道不良事件在多西环素中最为常见;中枢神经系统和胃肠道不良事件在米诺环素中最为常见。1998年1月至2003年8月,FDA的MedWatch数据包含美国报告的多西环素628起事件和米诺环素1099起事件。在此期间,美国共发放了约4763万张多西环素新处方和1523.4万张米诺环素新处方,根据FDA数据,多西环素的事件发生率为每百万13起,米诺环素为每百万72起。

结论

1998年至2003年期间,多西环素的处方量是米诺环素的3倍。两种药物的不良事件发生率都非常低,但多西环素报告的不良事件较少。尽管需要更多的直接比较不良事件频率的头对头临床试验,但这些来自单独报告的初步数据表明,多西环素发生不良事件的可能性可能比米诺环素小。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验